InsidersTradesSigma
Total declarations
Company
▲ Purchases (15 ops.)
▼ Sales (0 ops.)
Explore the detailed record of transactions filed by Krogulski Kenneth, Director. Insider active across 1 companies, notably Cumberland Pharmaceuticals INC. In total, 20 reports have been logged. Total volume traded: €3k. The latest transaction was disclosed on 1 June 2022 — Acquisition. Regulator: SEC (Form 4). All data is free.
Declarations20 total
€244127 shares@ €1.92410.0003% mcap2.1% of flow
Common Stock
SEC:0001209191-22-040099:0·
Ideal exit: 26 Feb 2023 (T+270)
€235101 shares@ €2.33130.0003% mcap2.0% of flow
Common Stock
SEC:0001209191-22-035983:0·
Ideal exit: 27 Jan 2023 (T+270)
€23594 shares@ €2.50440.0003% mcap2.0% of flow
Common Stock
SEC:0001209191-22-027643:0·
Ideal exit: 11 Jan 2023 (T+270)
€2,3611,000 shares@ €2.36110.0029% mcap20.5% of flow
Common Stock
SEC:0001209191-22-026148:0·
€27475 shares@ €3.65390.0003% mcap6.5% of flow
Common Stock
SEC:0001209191-22-002451·
Ideal exit: 28 Aug 2022 (T+270)
€27475 shares@ €3.65390.0003% mcap2.4% of flow
Common Stock
SEC:0001209191-22-002451:0·
Ideal exit: 28 Aug 2022 (T+270)
€19685 shares@ €2.31040.0002% mcap4.6% of flow
Common Stock
SEC:0001209191-21-067883·
Ideal exit: 29 Jul 2022 (T+270)
€19685 shares@ €2.31040.0002% mcap1.7% of flow
Common Stock
SEC:0001209191-21-067883:0·
Ideal exit: 29 Jul 2022 (T+270)
€19885 shares@ €2.32410.0002% mcap4.7% of flow
Common Stock
SEC:0001209191-21-063219·
Ideal exit: 28 Jun 2022 (T+270)
€19885 shares@ €2.32410.0002% mcap1.7% of flow
Common Stock
SEC:0001209191-21-063219:0·
Ideal exit: 28 Jun 2022 (T+270)
€20785 shares@ €2.43220.0003% mcap4.9% of flow
Common Stock
SEC:0001209191-21-058512·
Ideal exit: 29 May 2022 (T+270)
€20785 shares@ €2.43220.0003% mcap1.8% of flow
Common Stock
SEC:0001209191-21-058512:0·
Ideal exit: 29 May 2022 (T+270)
€23985 shares@ €2.81270.0003% mcap5.6% of flow
Common Stock
SEC:0001209191-21-055480·
Ideal exit: 29 Apr 2022 (T+270)
€23985 shares@ €2.81270.0003% mcap2.1% of flow
Common Stock
SEC:0001209191-21-055480:0·
Ideal exit: 29 Apr 2022 (T+270)
€20985 shares@ €2.45650.0003% mcap4.9% of flow
Common Stock
SEC:0001209191-21-051443·
Ideal exit: 28 Mar 2022 (T+270)
€20985 shares@ €2.45650.0003% mcap1.8% of flow
Common Stock
SEC:0001209191-21-051443:0·
Ideal exit: 28 Mar 2022 (T+270)
€20585 shares@ €2.41120.0003% mcap4.8% of flow
Common Stock
SEC:0001209191-21-046212·
€20585 shares@ €2.41120.0003% mcap1.8% of flow
Common Stock
SEC:0001209191-21-046212:0·
€2,7061,000 shares@ €2.70550.0033% mcap23.4% of flow
Common Stock
SEC:0001209191-21-039931:0·
€2,7061,000 shares@ €2.70550.0033% mcap63.9% of flow
Common Stock
SEC:0001209191-21-039931·
20 of 20 declarations
About Krogulski Kenneth
Kenneth Krogulski is an executive at CUMBERLAND PHARMACEUTICALS INC.
